(Q44016845)

English

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

scientific article published in July 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

hypercholesterolemia

0 references

1 reference

based on heuristic

inferred from title

author name string

Yoshihiro Noji

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Toshinori Higashikata

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Akihiro Inazu

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Atsushi Nohara

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Kosei Ueda

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Susumu Miyamoto

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Kouji Kajinami

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Tadayoshi Takegoshi

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Junji Koizumi

9

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Hiroshi Mabuchi

10

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Hokuriku NK-104 Study Group

11

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

1 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Atherosclerosis

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

163

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

157-164

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Development of coronary heart disease in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Matrix metalloproteinases and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Matrix metalloproteinases and coronary artery disease: a novel therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Serum apolipoproteins in heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Serum lipid and lipoprotein levels in Japanese patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) expression in developing human bone: potential roles in skeletal development

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900765-1

7 January 2021

Identifiers

10.1016/S0021-9150(01)00765-1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44016845&oldid=2105666503"